The company noted that new clinical study results demonstrated the feasibility of using RenalGuard-guided diuretic therapy to optimize fluid management in ADHF patients while relieving related symptoms.

RenalGuard-guided diuretic therapy has been developed to manage fluids during diuretic therapy for heart failure patients and reduce number of symptoms related to heart failure.

The therapy can provide clinicians better control over diuretic therapy by allowing precise and predictable management of a patient’s fluid levels.

The first-in-human clinical study assessed nine patients hospitalized for ADHF. They are provided with 24 hours of standard diuretic therapy with intravenous furosemide, followed by 24 hours of diuretics in conjunction with RenalGuard-guided diuretic therapy.

Results showed that clinicians can achieve a safe rate of fluid loss by accelerating high urine rates and maintaining intravascular volume using the treatment.

Average urine output measured over 24 hours of standard diuretic therapy was 1,961mL, while RenalGuard-guided diuretic therapy was applied in conjunction with diuretic therapy over the next 24 hours and average urine output increased to 4,771mL.

RenalGuard Solutions CEO Jim Dillon said: “We are thrilled to reveal late-breaking data that demonstrates a promising step towards a new therapy for patients suffering from Acute Decompensated Heart Failure.

“RenalGuard-Guided Diuretic Therapy has the potential to establish a new front-line standard of care for heart failure patients, allowing physicians to maximize fluid removal while protecting patients from the potential negative impact of excessive fluid loss.”

ADHF is a sudden onset of heart failure symptoms, which generally include difficulty breathing (dyspnea), swelling in the extremities and fatigue.

Diuretic therapy is the current treatment for ADHF, which enables to restore healthy fluid levels in the kidneys and across the body.

RenalGuard Solutions is engaged in the development of advanced fluid management technologies for the cardiac and vascular markets.